Skip to main content

01.07.2016 | Melanoma (RJ Sullivan, Section Editor) | Ausgabe 7/2016

Current Oncology Reports 7/2016

Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy

Current Oncology Reports > Ausgabe 7/2016
Sangeetha M. Reddy, Alexandre Reuben, Jennifer A. Wargo
Wichtige Hinweise
This article is part of the Topical Collection on Melanoma


The identification of key driver mutations in melanoma has led to the development of targeted therapies aimed at BRAF and MEK, but responses are often limited in duration. There is growing evidence that MAPK pathway activation impairs antitumor immunity and that targeting this pathway may enhance responses to immunotherapies. There is also evidence that immune mechanisms of resistance to targeted therapy exist, providing the rationale for combining targeted therapy with immunotherapy. Preclinical studies have demonstrated synergy in combining these strategies, and combination clinical trials are ongoing. It is, however, becoming clear that additional translational studies are needed to better understand toxicity, proper timing, and sequence of therapy, as well as the utility of multidrug regimens and effects of other targeted agents on antitumor immunity. Insights gained through translational research in preclinical models and clinical studies will provide mechanistic insight into therapeutic response and resistance and help devise rational strategies to enhance therapeutic responses.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen! 

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 7/2016

Current Oncology Reports 7/2016 Zur Ausgabe

Integrative Care (C Lammersfeld, Section Editor)

The Gut Microbiome and Obesity

Translational Oncology (L Vecchione, Section Editor)

Personalised Treatment in Gastric Cancer: Myth or Reality?

Palliative Medicine (A Jatoi, Section Editor)

“The Talk:” Discussing Hospice Care

Integrative Care (C Lammersfeld, Section Editor)

The Use of Medical Marijuana in Cancer

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.


Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.